-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Buy on Arcus Biosciences, Raises Price Target to $34

Benzinga·05/07/2026 16:21:28
Listen to the news
Goldman Sachs analyst Richard Law maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $30 to $34.